Product News for July 2025

RX Product

Lenacapavir (Yeztugo)

From: Gilead Sciences

The FDA approved lenacapavir for the prevention of HIV as preexposure prophylaxis (PrEP), marking a significant advance in PrEP as a twice-yearly injectable HIV-1 capsid inhibitor. The PURPOSE 1 (NCT04994509) trial showed that lenacapavir was highly effective, with a 100% reduction in HIV infections. The PURPOSE 2 trial (NCT04925752) also showed that lenacapavir was highly effective, with 99.9% of participants in the lenacapavir arm not acquiring HIV infection despite high reported levels of sexual behavior and other sexually transmitted infections among trial participants. The twice-yearly injection has the potential to significantly improve PrEP adherence, reducing HIV infections.

For more information: yeztugohcp.com

Dupilumab (Dupixent)

From: Sanofi and Regeneron

Dupilumab was recently approved by the FDA for the treatment of adults with bullous pemphigoid, marking the first and only targeted treatment for this condition. The approval is based on data from a pivotal study that met the primary and all key secondary end points in adults with moderate to severe disease. In the study, 5 times more patients in the dupilumab arm achieved sustained disease remission compared with those on placebo. Overall rates of adverse events were 96% in the dupilumab arm and 96% in the placebo arm.

For more information: dupixenthcp.com

OTC Product

Nasacort Allergy 24-Hour Nasal Spray

From: Opella Healthcare Group

Nasacort Allergy 24-Hour Nasal Spray (triamcinolone acetonide) is now available without a prescription in the US, making it the first and only OTC corticosteroid nasal spray providing 24-hour relief from nasal allergy symptoms—including congestion, sneezing, itching, and runny nose—for adults and children aged 2 and up. This transition from prescription to OTC expands access to a potent, long-acting allergy treatment, allowing pharmacists to recommend it directly, enhance seasonal relief offerings, and support better symptom management without the need for a doctor visit.

For more information: nasacort.com/en-us

Generic Product

Raltegravir Potassium Tablets

From: Lupin Pharmaceuticals

Compare to: Isentress HD

The recent FDA approval of generic raltegravir potassium tablets 600 mg, a first-time generic for Isentress HD, marks a significant development for pharmacists involved in HIV care. As a key integrase inhibitor used in the treatment of HIV-1 infection, raltegravir is a cornerstone in many antiretroviral regimens. The availability of a generic version may lead to improved medication access and adherence by reducing costs for patients and payers. For pharmacists, this approval provides an opportunity to promote cost-effective therapy, counsel patients on transitioning from brand to generic, and support continuity of care in HIV management.

For more information: lupin.com